Study of RMC-6236 in Patients With… · NCT05379985

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS is a phase 1/2 interventional study registered as NCT05379985 by Revolution Medicines, Inc., with 754 participants planned, started 2022-05-31 and due to reach its primary completion in 2027-05-31. Interventions recorded: RMC-6236. Conditions listed: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors. No results are recorded here; the registry entry is the source.

Setting

A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Phase

Phase 1/2

Sponsor

Revolution Medicines, Inc.

Registry

NCT05379985

Headline result

Second-line daraxonrasib 300 mg in 26 patients with RAS G12-mutated pancreatic cancer: objective response 35 percent, median progression-free survival 8.5 months, median overall survival 13.1 months; grade 3 or higher treatment-related adverse events in 30 percent of 168 pancreatic patients.

Started

2022-05-31

Reported

2026

Enrolled

754 enrolled

Outcomes

2top

In plain words

What these results mean for people, not percentages

754 enrolled

Objective response, second-line RAS G12 pancreatic cancer at 300 mgresponse endpoint

35 out of 100 people had their tumour shrink with Daraxonrasib 300 mg.

There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.

Overall survival, second-line RAS G12 pancreatic cancer at 300 mgsurvival endpoint

Median 13.1 months with Daraxonrasib 300 mg.
A median is a midpoint: half the people did better than this and half did worse.

Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.

Caveats

These results apply to the people the trial enrolled: A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS. People in a different situation may not see the same effect.

Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

754 enrolled.

Objective response, second-line RAS G12 pancreatic cancer at 300 mg

Daraxonrasib 300 mg35 of 100

n = 26

Download

95% CI 17 to 56; median duration of response 8.2 months

Source

Overall survival, second-line RAS G12 pancreatic cancer at 300 mg

Download

Source

Endpoint	Arm	n	Value	HR (95% CI)	p	Source
Objective response, second-line RAS G12 pancreatic cancer at 300 mg	Daraxonrasib 300 mg	26	35%	-	-	link
Overall survival, second-line RAS G12 pancreatic cancer at 300 mg	Daraxonrasib 300 mg	26	13.1 months	-	-	link

Notes

top

Pancreatic cohort of the phase 1/2 (NEJM 2026, Wolpin et al.): 168 previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma received daraxonrasib at 300 mg or less; treatment-related adverse events of any grade in 96 percent and grade 3 or higher in 30 percent (rash, diarrhoea, nausea, stomatitis, vomiting, fatigue the commonest). In 26 patients with RAS G12 mutations treated second line at 300 mg the response rate was 35 percent with median progression-free survival 8.5 and overall survival 13.1 months; in 38 with G12, G13 or Q61 mutations 29 percent, 8.1 and 15.6 months. These figures set the 300 mg phase 3 dose for RASolute 302.

Key papers

1top

observationalNew England Journal of Medicine 202617 citations

Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer

This is the paper Europe PMC returns for registry id NCT05379985 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

Connected

10top

cancers

Colorectal cancer Metastatic pancreatic ductal adenocarcinoma Non-small-cell lung cancer Pancreatic ductal adenocarcinoma Small-cell lung cancer

technologies

KRAS & RAS inhibitors

drugs

ApprovedSmall-molecule pan-RAS(ON) inhibitor

Daraxonrasib · Rasonque

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Outcomes

Notes

Key papers

Connected

Similar pages

cancers

technologies

drugs

companies

terms

key papers

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Outcomes

Notes

Key papers

Connected

Similar pages

cancers

technologies

drugs

companies

terms

key papers

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Overview

Outcomes

Notes

Key papers

Connected

Similar pages

cancers

technologies

drugs

companies

terms

key papers

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Overview

Outcomes

Notes

Key papers

Connected

Similar pages

cancers

technologies

drugs

companies

terms

key papers